Exosomal TUBB3 mRNA expression of metastatic castration‐resistant prostate cancer patients: Association with patient outcome under abiraterone. (28th July 2021)

• Record Type: Journal Article
• Authors: Zhu, Sha; Ni, Yuchao; Sun, Guangxi; Wang, Zilin; Chen, Junru; Zhang, Xingming; Zhao, Jinge; Zhu, Xudong; Dai, Jindong; Liu, Zhenhua; Liang, Jiayu; Zhang, Haoran; Zhang, Yaowen; Shen, Pengfei; Zeng, Hao
• Is Part Of: Cancer medicine. Volume 10:Number 18(2021)
• Page Start: 6282
• Page End: 6290
• Publication Date: 2021-07-28
• Subjects: abiraterone acetate -- exosomes -- messenger -- prostatic neoplasms -- RNA -- TUBB3; 616.994005
• DOI: 10.1002/cam4.4168
• Languages: English
• ISSNs: 2045-7634

Abstract

Abstract: Background: To use ddPCR to quantify plasma exosomal class III β‐tubulin (βIII‐tubulin, TUBB3, encoded by the TUBB3 gene) mRNA expression in metastatic castration‐resistant prostate cancer (mCRPC) patients, and study the association of this expression with abiraterone efficacy. Methods: Blood samples were prospectively collected from 52 mCRPC patients using abiraterone as first‐line therapy to measure plasma exosomal TUBB3 mRNA expression value before the initiation of abiraterone. Study endpoints were PSA response rate, PSA‐progression‐free survival (PSA‐PFS), and overall survival (OS, from CRPC to death). Results: Patients with positive exosomal TUBB3 expression showed shorter PSA‐PFS (negative TUBB3 vs. positive TUBB3 : 11.0 vs. 7.9 months; p = 0.014). Further analysis demonstrated that patients with strongly positive exosomal TUBB3 (>20 copies/20 µl) was associated with even shorter PSA‐PFS (negative TUBB3 vs. positive TUBB3 [<20 copies/20 µl] vs. strongly positive TUBB3 [>20 copies/20 µl]: 11.0 vs. 8.3 vs. 3.6 months, p = 0.005). In multivariate analyzes, TUBB3 (+) (HR: 2.114, p = 0.033) and ECOG score >2 (HR: 3.039, p = 0.006) were independent prognosticators of poor PSA‐PFS. PSA response and OS did not present significant differences. Conclusion: The exosomal TUBB3 mRNA expression level is associated with poor PSA‐PFS of abiraterone in mCRPC patients. The detection of exosomal TUBB3 can be valuable in their management. Abstract : In this study, we presented this novel, non‐invasive biomarker for abiraterone resistance in mCRPC patients using a ddPCR approach to quantificationally measure the exosomal TUBB3 mRNA expression. We found that a higher TUBB3 level is correlated with shorter progression time after first‐line abiraterone treatment in mCRPC patients.